RBC Capital Keeps Their Buy Rating on Repligen (RGEN)

1 day ago · RBC Capital analyst Conor McNamara maintained a Buy rating on Repligen (RGEN – Research Report) on January 10 and set a price target of $207.00. The company’s shares …

$207.00
OFF

RBC Capital Keeps Their Buy Rating On Repligen (RGEN)

2 weeks from now

1 day ago · RBC Capital analyst Conor McNamara maintained a Buy rating on Repligen (RGEN – Research Report) on January 10 and set a price target of $207.00. The company’s shares …

businessinsider.com

$200.00
OFF

RBC Capital Sticks To Their Buy Rating For Repligen (RGEN)

2 weeks from now

Jan 26, 2024 · RBC Capital analyst Conor McNamara maintained a Buy rating on Repligen ( RGEN – Research Report) on January 24 and set a price target of $200.00. The company’s …

businessinsider.com

$207.00
OFF

RBC Capital Reaffirms Their Buy Rating On Repligen (RGEN)

2 weeks from now

Dec 10, 2024 · In a report released on December 8, Conor McNamara from RBC Capital maintained a Buy rating on Repligen (RGEN – Research Report), with a price target of $207.00.

businessinsider.com

$185.20
OFF

Analysts Set Repligen Co. (NASDAQ:RGEN) Price Target At $185.20

2 weeks from now

2 hours ago · Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th.

etfdailynews.com

$207
OFF

RBC Lifts Price Target On Repligen To $207 From $205, Keeps …

2 weeks from now

Dec 9, 2024 · -- Repligen has an average rating of overweight and mean price target of $193.25, according to analysts polled by FactSet. ...

marketscreener.com

87%
OFF

Repligen (NASDAQ:RGEN) Stock, Analyst Ratings, Price Targets

2 weeks from now

Dec 31, 2018 · With an average price target of $183.33 between Canaccord Genuity, RBC Capital, and Wells Fargo, there's an implied 25.87% upside for Repligen Corp from these most …

benzinga.com

$205.00
OFF

Brokerages Set Repligen Co. (NASDAQ:RGEN) Price Target At …

2 weeks from now

Oct 29, 2024 · A number of brokerages recently issued reports on RGEN. UBS Group decreased their price target on shares of Repligen from $205.00 to $185.00 and set a "buy" rating for the …

marketbeat.com

71%
OFF

Analyst Ratings Of REPLIGEN CORP(NASDAQ:RGEN) Stock

2 weeks from now

The Buy consensus is the weighted average rating of the current analysts ratings. Analysts have set a mean price target forecast of 208.62. This target is 26.71% above the current price. …

chartmill.com

$205.00
OFF

Repligen (RGEN) Receives A Buy From RBC Capital

2 weeks from now

Sep 25, 2024 · RBC Capital analyst Conor McNamara maintained a Buy rating on Repligen (RGEN – Research Report) on September 22 and set a price target of $205.00. The …

businessinsider.com

FAQs about RBC Capital Keeps Their Buy Rating on Repligen (RGEN) Coupon?

Should you buy Repligen co (RGEN) stock?

Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. ...

Is Repligen a good stock to buy?

Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. ...

What is the average 12 month price target for Repligen?

The average 12 month price target among analysts that have issued ratings on the stock in the last year is $185.20. A number of equities analysts have issued reports on the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. ...

How much will Repligen (Repligen) earn per share?

On average, sell-side analysts expect that Repligen will post 1.54 earnings per share for the current year. (Get Free Report Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. ...

Who is Repligen (RGEN)?

Begin your TipRanks Premium journey today. Repligen (RGEN) Company Description: Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). ...

How do I receive news & ratings for Repligen?

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter. ...